

The Clinical Pharmacogenetics Implementation Consortium Guideline for *SLCO1B1*, *ABCG2*, and *CYP2C9* genotypes and Statin-Associated Musculoskeletal Symptoms

Rhonda M. Cooper-DeHoff^{1,2,†}, Mikko Niemi^{3,4,5,†}, Laura B. Ramsey^{6,7}, Jasmine A. Luzum⁸, E. Katriina Tarkiainen^{3,4,5}, Robert J. Straka⁹, Li Gong¹⁰, Sony Tuteja¹¹, Russell A. Wilke¹², Mia Wadelius¹³, Eric A. Larson¹², Dan M. Roden^{14,15}, Teri E. Klein¹⁰, Sook Wah Yee¹⁶, Ronald M. Krauss¹⁷, Richard M. Turner¹⁸, Latha Palaniappan¹⁹, Andrea Gaedigk²⁰, Kathleen M. Giacomini¹⁶, Kelly E. Caudle²¹ and Deepak Voora^{22,*}

Statins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed medications in the world. Statin-associated musculoskeletal symptoms (SAMS) impact statin adherence and ultimately can impede the long-term effectiveness of statin therapy. There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. *SLCO1B1* encodes a transporter (*SLCO1B1*; alternative names include *OATP1B1* or *OATP-C*) that facilitates the hepatic uptake of all statins. *ABCG2* encodes an efflux transporter (*BCRP*) that modulates the absorption and disposition of rosuvastatin. *CYP2C9* encodes a phase I drug metabolizing enzyme responsible for the oxidation of some statins. Genetic variation in each of these genes alters systemic exposure to statins (i.e., simvastatin, rosuvastatin, pravastatin, pitavastatin, atorvastatin, fluvastatin, lovastatin), which can increase the risk for SAMS. We summarize the literature supporting these associations and provide therapeutic recommendations for statins based on *SLCO1B1*, *ABCG2*, and *CYP2C9* genotype with the goal of improving the overall safety, adherence, and effectiveness of statin therapy. This document replaces the 2012 and 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for *SLCO1B1* and simvastatin-induced myopathy.

In 2012, the Clinical Pharmacogenetics Implementation Consortium (CPIC) published a gene-based prescribing guideline for simvastatin based on *SLCO1B1* genotype,¹ and this guideline was updated in 2014.² The current document replaces the original 2012 guideline and the 2014 update. New to this guideline are the addition of recommendations for *CYP2C9* and *ABCG2* and addition of recommendations for all statins. We summarize literature

supporting how *SLCO1B1*, *ABCG2*, and *CYP2C9* genotype test results should be applied to optimize new or existing statin therapy to reduce the risk of statin-associated musculoskeletal symptoms (SAMS). This CPIC document serves as a guide for selecting the most appropriate statin and the optimal dose *if* pharmacogenetic test results are available (not whether to perform pharmacogenetic testing). Decisions concerning when, in whom, and at what

¹Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA; ²Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA; ³Department of Clinical Pharmacology, Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland; ⁴HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland; ⁵Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland; ⁶Divisions of Clinical Pharmacology & Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; ⁷Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA; ⁸Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA; ⁹Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA; ¹⁰Department of Biomedical Data Science, School of Medicine, Stanford University, Stanford, California, USA; ¹¹Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; ¹²Department of Internal Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota, USA; ¹³Department of Medical Sciences, Clinical Pharmacogenomics & Science for Life Laboratory, Uppsala University, Uppsala, Sweden; ¹⁴Division of Cardiovascular Medicine and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; ¹⁵Department of Pharmacology and Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA; ¹⁶Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA; ¹⁷Departments of Pediatrics and Medicine, University of California, San Francisco, California, USA; ¹⁸The Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK; ¹⁹Division of Primary Care and Population Health, Stanford University School of Medicine, Stanford, California, USA; ²⁰Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City and School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA; ²¹Division of Pharmaceutical Sciences, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; ²²Department of Medicine, Duke Center for Applied Genomics & Precision Medicine, Duke University School of Medicine, Durham, North Carolina, USA. *Correspondence: Deepak Voora (deepak.voora@duke.edu; contact@cpicpgx.org)

[†]Shared first author.

Received December 8, 2021; accepted February 2, 2022. doi:10.1002/cpt.2557

intensity statin therapy should be initiated are beyond the scope of this manuscript and are extensively reviewed elsewhere.³ Given the balance of SAMS risk vs. known cardiovascular disease benefit, for patients who are candidates for new statin therapy, pharmacogenetic test results may provide additional useful information. For patients currently prescribed statin therapy, depending on how long the patient has been tolerating the statin, pharmacogenetic test results may be used as the basis for changing to another statin type or dose. Statin therapy should neither be discontinued nor avoided based on *SLCO1B1*, *ABCG2*, or *CYP2C9* genotype results for patients with an indication for statin therapy, especially if the statin therapy is based on the shared decision making between patient and provider. Although evidence review included other outcomes such as the impact of genetic variation on lipid-lowering, the recommendations provided in this guideline are based on the effect of genetic variations on the risk of SAMS.

FOCUSED LITERATURE REVIEW AND UPDATE

A systematic literature review was conducted, focusing on associations of statin-related clinical endpoints (efficacy and toxicity) with gene variants of *SLCO1B1*, *ABCG2*, *CYP2C9*, *CYP3A4*, *CYP3A5*, and *HMGCR* (details in **Tables S1–S5 and Supplement**). Based on the evidence review and insufficient evidence to support clinical implementation, no recommendations are provided for *HMGCR*, *CYP3A4*, or *CYP3A5* (see **Tables S4 and S5** and the supplement text for details). Hence, this guideline will focus only on *SLCO1B1*, *ABCG2*, and *CYP2C9* genetic variation as these have been shown to impact statin exposure and risk of SAMS. As the previous CPIC guideline focused only on *SLCO1B1* and simvastatin, the *SLCO1B1* recommendation provided in this guideline should be considered a replacement of the previous *SLCO1B1* and simvastatin recommendations.²

GENES: *SLCO1B1*, *ABCG2*, AND *CYP2C9*

Background

SLCO1B1. *SLCO1B1* (solute carrier organic anion transporter family member 1B1) (alternative protein names include OATP1B1 and OATP-C) is used in this guideline to designate the protein product of the *SLCO1B1* gene. *SLCO1B1* facilitates the hepatic uptake of statins, as well as other exogenous and endogenous compounds (e.g., bilirubin and 17-beta-glucuronosyl estradiol).⁴ Decreased function of this transporter (inherited through genetic variability or acquired through drug-mediated inhibition) can markedly increase the systemic exposure to statins, the putative causal factor underlying the link to SAMS.⁵ The *SLCO1B1* gene locus occupies 109 kilobase (kb) on chromosome 12 (Chr 12p12.2) and, although many single nucleotide variants (SNVs) have been identified in this gene, only a few are known to have a clinically relevant functional impact (***SLCO1B1* Allele Definition Table and *SLCO1B1* Allele Functionality Table**^{6,7}). The common c.521T>C variant, rs4149056, produces a p.V174A substitution and is contained within *SLCO1B1**5 and *15 haplotypes. The *SLCO1B1**17 haplotype also contains the c.521T>C variant; however, this allele designation no longer

exists (the Pharmacogene Variation Consortium (PharmVar⁸) recently merged this allele with *SLCO1B1**15). The minor C allele at c.521T>C has been associated with decreased transport function *in vitro* and increased systemic exposure to several drugs *in vivo* (See **Table S1**). Differences in allele frequencies have been observed across multiple ancestries and geographically diverse groups (***SLCO1B1* Allele Frequency Table**^{6,7}).

ABCG2. *ABCG2*, which encodes the transporter adenosine triphosphate (ATP)-binding cassette G2 (also known as breast cancer resistance protein, BCRP) is expressed in many different tissues, including liver, blood-brain barrier, and intestine. *ABCG2* facilitates the export of compounds into the extracellular space. The *ABCG2* gene locus spans over 66 kb on chromosome 4 (Chr 4q22.1). The common variant p.Q141K (c.421C>A, rs2231142) has been studied extensively; the minor A allele is associated with 30–40% reduced protein expression compared with the reference allele and with increased plasma levels of rosuvastatin (**Table S2**) (***ABCG2* Allele Definition Table and *ABCG2* Allele Functionality Table**^{6,7}). Differences in allele frequencies have been observed across multiple geographically, racially, and ethnically diverse groups (***ABCG2* Allele Frequency Table**^{6,7}).

CYP2C9. The cytochrome P450 2C9 (*CYP2C9*) enzyme contributes to the phase I metabolism of many drugs. *CYP2C9* is one of the *CYP2C* genes clustered in a 500-kb region on 10q24 (Chr 10q23.33). The *CYP2C9* gene is highly polymorphic, with at least 71 variant alleles (***CYP2C9* Allele Definition Table**^{6,7,9}). Differences in allele frequencies have been observed across multiple geographically, racially, and ethnically diverse groups (***CYP2C9* Allele Frequency Table**^{6,7}). The two most extensively studied variants are *CYP2C9**2 (p.R144C; rs1799853) and *CYP2C9**3 (p.I359L; rs1057910),¹⁰ which reduce *CYP2C9* function by ~ 30–40% and 80%, respectively, and lead to increased systemic exposure to fluvastatin (***CYP2C9* Allele Functionality Table**^{6,7}).

Genetic test interpretation

SLCO1B1. The assignment of the predicted *SLCO1B1* phenotype, based on star (*) allele diplotypes, has been summarized in **Table 1**. *SLCO1B1* haplotypes are often named using star allele nomenclature, representing various SNVs alone or in combination (PharmVar⁸ and ***SLCO1B1* Allele Definition Table**^{6,7,11}) that are associated with altered *SLCO1B1* protein expression or function (**Allele Functionality Table**^{6,7}). The combination of alleles is used to determine a patient's diplotype (often also referred to as genotype), which can then be used to infer an individual's predicted phenotype (**Table 1; *SLCO1B1* Diplotype to Phenotype Table**^{6,7}). Individuals with two increased function alleles (*SLCO1B1**14/*14) have an *SLCO1B1* increased function phenotype. Individuals with only normal function alleles (*SLCO1B1**1/*1) or a normal function allele plus an increased function allele (*SLCO1B1**1/*14) have an *SLCO1B1* normal function phenotype, while individuals with one no function allele (e.g., *SLCO1B1**5) and one normal function or increased function

Table 1 Assignment of predicted *SLCO1B1*, *ABCG2*, and *CYP2C9* likely phenotype based on genotype

Gene	Phenotype ^{a,b}	Activity score (if applicable)	Genotype	Examples of diplotypes
<i>SLCO1B1</i>	Increased function	n/a	An individual carrying two increased function alleles	*14/*14
	Normal function	n/a	An individual carrying two normal function alleles or one normal plus one increased function allele	*1/*1, *1/*14
	Decreased function	n/a	An individual carrying one normal or increased function allele plus one no function allele	*1/*5, *1/*15,
	Possible decreased function	n/a	An individual carrying one no function allele plus one uncertain/unknown function allele	*5/*6, *15/*10, *5/*43
	Poor function	n/a	An individual carrying two no function alleles	*5/*5, *5/*15, *15/*15
	Indeterminate	n/a	An individual carrying one normal function allele plus one uncertain or unknown function allele OR allele combinations with uncertain and/or unknown function alleles	*1/*7, *1/*10, *7/*10
<i>ABCG2</i>	Normal function	n/a	An individual carrying two normal function alleles	c.421 C/C (rs2231142)
	Decreased function	n/a	An individual carrying one normal function allele plus one decreased function allele	c.421 C/A (rs2231142)
	Poor function	n/a	An individual carrying two decreased function alleles	c.421 A/A (rs2231142)
<i>CYP2C9</i>	Normal metabolizer	2	An individual carrying two normal function alleles	*1/*1
	Intermediate metabolizer	1.5	An individual carrying one normal function allele plus one decreased function allele OR	*1/*2
		1	one normal function allele plus one no function allele OR two decreased function alleles	*1/*3, *2/*2
	Poor metabolizer	0.5	An individual carrying one no function allele plus one decreased function allele OR	*2/*3
		0	two no function alleles	*3/*3
	Indeterminate	n/a	An individual carrying allele combinations with uncertain and/or unknown function alleles	*1/*7, *1/*10, *7/*10

n/a, not applicable.

^aAllele and phenotype frequencies vary by ancestral group (see **Frequency Table**^{6,7}).

^bAssignment of allele function and associated citations can be found in the **Allele Functionality Tables**^{6,7}. For a complete list of diplotypes and resulting phenotypes, see the **Diplotype to Phenotype Table**^{6,7}.

allele have an *SLCO1B1* decreased function phenotype and individuals with two no function alleles (e.g., *SLCO1B1**5/*5) have an *SLCO1B1* poor function phenotype.

The most common and well-studied variant in *SLCO1B1* is c.521T>C (rs4149056), and it can be genotyped alone (e.g., polymerase chain reaction–based single SNV assay) or multiplexed on a variety of array-based platforms. All *SLCO1B1* genetic tests should interrogate c.521T>C; however, while other less common variants in this gene may have limited evidence to guide action, they may also be important (*SLCO1B1* Allele Definition Table and *SLCO1B1* Allele Functionality Table^{6,7}).

ABCG2. Unlike *SLCO1B1* and *CYP2C9*, there is no star allele nomenclature to represent *ABCG2* variants at this time. Assignment of the predicted *ABCG2* phenotype is summarized in **Table 1**. An individual carrying one normal function allele plus one decreased function allele (rs2231142; c.421C>A) has *ABCG2* decreased function, and an individual with two decreased function alleles has *ABCG2* poor function. rs2231142 can be genotyped alone (e.g., polymerase chain reaction–based single SNP assay) or multiplexed on a variety of array-based platforms. Various commercial genotyping platforms include rs2231142 in panels of pharmacogenetic variants.¹²

CYP2C9. Most clinical laboratories reporting *CYP2C9* genotype use the star (*) allele nomenclature which can be found at PharmVar⁸ and in the ***CYP2C9* Allele Definition Table**.^{6,7} The combination of alleles is used to determine a patient's diplotype, which can then be used to infer an individual's predicted metabolizer phenotype (**Table 1; *CYP2C9* Diplotype to Phenotype Table**^{6,7}). Each allele's functional status is assigned an activity value ranging from 0 to 1 (e.g., 0 for no function, 0.5 for decreased function, and 1.0 for normal function), which are summed to calculate the activity score (AS) for each diplotype (***CYP2C9* Allele Functionality Table**^{6,7}). The *CYP2C9* AS is then translated into phenotype: individuals with an AS of 0 or 0.5 are poor metabolizers (PMs), those with an AS of 1 or 1.5 are intermediate metabolizers (IMs), and those with an AS of 2 are normal metabolizers (NMs) (**Table 1; *CYP2C9* Diplotype to Phenotype Table**^{6,7}). Because reference laboratories providing clinical *CYP2C9* genotyping may use varying methods to assign phenotypes, it is advisable to note a patient's *CYP2C9* diplotype and to refer to the ***CYP2C9* Diplotype to Phenotype Table** online for a complete list of possible diplotypes and phenotype assignments before making therapeutic decisions.

Available genetic test options

See the Genetic Testing Registry (www.ncbi.nlm.nih.gov/gtr/) for more information on commercially available clinical testing options.

Incidental findings

Genetic variability in *SLCO1B1* influences the hepatic uptake of other drugs (e.g., methotrexate)^{13,14} as well as important endogenous compounds (e.g., bilirubin).¹⁵ Complete *SLCO1B1* and *SLCO1B3* deficiency is associated with Rotor syndrome.¹⁵ Genetic polymorphisms in *ABCG2* influence absorption and disposition of many drugs, including anticancer drugs and antiviral drugs.¹⁶ In addition, genome-wide association studies reveal that *ABCG2* variants influence serum uric acid levels, risk for gout, and response to the antigout medication, allopurinol.^{17,18} In addition, null *ABCG2* expression is associated with the Junior blood group, which determines presence of the Jr(a) antigen.¹⁹ No diseases or conditions have been consistently or strongly linked to variation in *CYP2C9* independent of drug metabolism and response. *CYP2C9* IMs and PMs may be predisposed to serious bleeding during warfarin therapy and increased risk of phenytoin-related and nonsteroidal anti-inflammatory drug-related toxicities.^{20–23}

Other considerations

All studies in this literature review investigated each gene individually for SAMS. As high-throughput genotyping and more sequence-based analyses become more widely available, it is important to consider higher order interactions of these (and other) genes, in addition to epigenetic, drug-drug-gene, and gene-environment interactions in statin therapies.

DRUGS: STATINS (HMG-CoA REDUCTASE INHIBITORS)

Background

One in four Americans aged 40 and older use a statin.²⁴ In 2018, atorvastatin and simvastatin were the #1 and #10 most commonly

prescribed drugs in the United States, respectively. Statins have a wide therapeutic index. The most common statin-related adverse drug reaction is skeletal muscle toxicity which manifest as SAMS.²⁵ SAMS include a range of clinical entities from the most common (about 1 in 10), myalgia (pain without evidence of muscle degradation, i.e., creatine kinase levels < 3× normal); less common (about 1 in 2,000), myopathy (evidence of muscle degradation with or without myalgia, i.e., creatine kinase levels ≥3× normal); and rare (less than 1 in 10,000), rhabdomyolysis (severe muscle damage with risk for acute kidney injury).²⁶ Based on extrapolation from dose–response and drug–drug interaction data, most SAMS cases are likely statin concentration-dependent²⁷ due to direct statin myotoxicity. An alternative form of SAMS stems from an autoimmune-mediated necrotizing myopathy characterized by autoantibodies against HMGCR and is not considered further in this guideline's reference to SAMS.

The frequency of SAMS in clinical practice is higher than observed in blinded, placebo-controlled trials for reasons that can be attributed to differences in the types of patients enrolled in clinical trials vs. practice, the use of “run-in” periods in clinical trials, as well as a potential “nocebo” effect of statins. Nevertheless, patients and providers frequently report SAMS in clinical practice and data from the National Health and Nutrition Examination Survey (NHANES) suggesting that the “number needed to harm” may be as high as 17.²⁸ Although described as “mild,” SAMS frequently leads to statin discontinuation, thus leading to higher cholesterol levels and a higher risk for cardiovascular disease if statins are not reinitiated.^{29,30}

Linking genetic variability to variability in drug-related phenotypes

We applied a systematic approach to reviewing the evidence underlying the clinical validity of genetic associations with statin-related phenotypes including statin pharmacokinetics (*in vivo* and *in vitro*), SAMS, hepatotoxicity, lab-based efficacy (cholesterol lowering), and clinical efficacy (vascular event reduction). Statins evaluated included simvastatin, rosuvastatin, pravastatin, pitavastatin, atorvastatin, fluvastatin, and lovastatin. We reviewed the evidence for *SLCO1B1*, *ABCG2*, *CYP2C9*, *CYP3A4/5*, and *HMGCR* and applied a grading system for each piece of evidence that evaluated an association between genotype and phenotype (**Tables S1–S5**). We found the highest levels of evidence for *SLCO1B1* (all statins), *ABCG2* (rosuvastatin), and *CYP2C9* (fluvastatin), and this evidence forms the basis for therapeutic recommendations in the current guideline. Evidence tables for *CYP3A4/5* and *HMGCR* are provided in the supplement (**Tables S4 and S5**). Based on weak evidence and the lack of conclusive clinical action based on genotype, no recommendations are provided for statins and *CYP3A4/5* and *HMGCR*. See section “Linking genetic variability to variability in drug-related phenotypes” in the supplement for discussion of evidence.

Therapeutic recommendations

SLCO1B1. The American College of Cardiology and the American Heart Association issued an updated clinical practice guideline for the management of blood cholesterol in 2018. In those

guidelines, statins at various daily doses are classified as high-intensity, medium-intensity, or low-intensity statins based on expected ranges of low-density lipoprotein (LDL) cholesterol lowering. For example, they recommend initiation of high-intensity statins in patients with evidence of clinical atherosclerotic cardiovascular disease, which may include atorvastatin at 40 or 80 mg once daily or rosuvastatin at 20 or 40 mg once daily.³ **Figure 1** is designed to be used in conjunction with the aforementioned guideline, as it provides statin recommendations, including preferred statin intensity and statin dose, stratified by *SLCO1B1* phenotype (i.e., decreased or poor function). Statin and statin doses indicated in the light grey boxes can be prescribed with the lowest risk for SAMS. Statin and statin doses indicated in dark grey boxes should be used with caution (possible increased risk for SAMS), and statin and statin doses indicated in black boxes should be avoided as the available evidence suggests that they are associated with increased risk of harm. The recommendations are based on the combination of available pharmacokinetic and SAMS risk data, in most cases, and are informed by the number of available statin options within each intensity. Some statins and doses in **Figure 1** were derived based on pharmacokinetic data only (see **Figure 1** legend). Full recommendations can be found in **Table 2**.

ABCG2. Recommendations for *ABCG2* are specific to rosuvastatin (**Table 3**). For individuals who have *ABCG2* poor function, a rosuvastatin starting dose of ≤ 20 mg is recommended; however, if a dose greater than 20 mg is needed for desired efficacy, an alternative statin or combination therapy (e.g., statin + ezetimibe) is recommended. Although the risk of myopathy is unknown, rosuvastatin exposure (area under the concentration-time curve (AUC)) was 144% greater in those with the c.421AA genotype than the c.421CC genotype (wild type);³¹ thus, the recommendation is based primarily on pharmacokinetic data. Likely because of the higher hepatic exposure, the *ABCG2* c.421A variant has also been associated with improved cholesterol lowering response to rosuvastatin in large genome-wide association studies.³² Selection and dosing of rosuvastatin should also consider Asian ancestry (**Table 3**, see the **Supplemental Material** for more discussion). Atorvastatin pharmacokinetics are also affected by *ABCG2* genetic variation; however, at this time, there is insufficient evidence to provide a recommendation (no recommendation, CPIC level C). As noted previously, there is also limited evidence for providing recommendations for other statins based on genetic variation in *ABCG2*.


CYP2C9. Recommendations for fluvastatin based on *CYP2C9* phenotype are available in **Table 4**. Genetic variations in *CYP2C9* are associated with increased exposure to fluvastatin (**Table S3**), but the pharmacokinetics or pharmacodynamics of other statins are not affected.

CYP2C9 IMs should avoid fluvastatin doses greater than 40 mg while *CYP2C9* PMs should avoid doses greater than 20 mg. If higher doses are required for desired efficacy, an alternative statin should be considered. If fluvastatin therapy is warranted, consider combination therapy of fluvastatin (40 mg in IMs and 20 mg in PMs) plus a nonstatin lipid-lowering agent.

Combinatorial gene-based recommendations. Although specific combinations of *SLCO1B1* with *ABCG2* or *CYP2C9* genotypes are likely to result in additive effects on the pharmacokinetic properties of rosuvastatin or fluvastatin, respectively, little information is available on how to adjust initial doses based on combined genotype information.³³ Combinatorial gene-based recommendations generated by extrapolating evidence supporting the single gene associations and assuming that they are additive, are provided for rosuvastatin in **Table 5** and fluvastatin in **Table 6**. Because there are limited clinical or pharmacokinetic data regarding these combinatorial phenotypes, pharmacotherapy recommendations are classified as optional for the high-risk phenotype groups (e.g., *SLCO1B1* no function plus *ABCG2* no function). In the case of fluvastatin recommendations for *CYP2C9* poor metabolizers who also have *SLCO1B1* decreased or poor function, we recommend prescribing an alternative agent rather than prescribing a lower dose based on the available dosage forms (no dosage form less than 20 mg is available for fluvastatin).

General guidance for patients already receiving statin therapy. The therapeutic recommendations described herein predominately apply to a new or a revision (dose or type) to statin prescription. However, given the increasing shift towards panel-based testing for multiple pharmacogenes, and the vast number of individuals already receiving statin therapy, an important issue to consider is how to manage statin therapy for patients that may already be receiving statin therapy, and then receive a genotype result, particularly for those whose genotype indicates that they are in a higher risk category based on the currently prescribed statin (i.e., moderate or high SAMS risk in **Figure 1**). For patients with *SLCO1B1* genotype-statin dose combinations that fall within the moderate SAMS risk categories in **Figure 1** who have already been on a stable statin and dose for at least 4 weeks without any symptoms suggestive of SAMS, then it is reasonable to continue that statin and dose long-term.³⁴ If those patients have been receiving that statin therapy for less than 4 weeks, then clinicians may consider changing to a lower SAMS risk statin/dose in order to prevent the development of SAMS. For patients that fall into the high SAMS risk categories, and they have been taking that statin therapy for at least 1 year without any negative effects, then it is deemed safe to continue that statin therapy long-term. If those patients have been taking statin therapy for less than 1 year, then clinicians may consider changing to a lower SAMS risk statin/dose in order to reduce the risk for development of SAMS. These recommendations for the minimum duration of statin therapy for continued safe use long-term are primarily based on expert opinion and the onset of SAMS observed for simvastatin in different *SLCO1B1* genotypes in a single prospective clinical trial.³⁴

Pediatrics. At the time of this writing, there are no data available regarding *SLCO1B1* genotype effects on statin response or myopathy in pediatric patients. However, pharmacokinetic data show that the rs4149056 SNV in *SLCO1B1* may affect the disposition of simvastatin more in children compared with adults, and the variant has equivalent impact on pravastatin and rosuvastatin pharmacokinetics between children and adults.³⁵⁻³⁷



Legend: **Light gray boxes:** Prescribe stated starting dose. **Dark gray boxes:** Prescriber should be aware of possible increased risk of increased exposure and myopathy. **Black boxes:** Consider a reduced dose or alternative statin. **All boxes:** Doses indicated are total daily dose. Dose recommendations are based on clinical toxicity data when available. ^aStatin intensity as recommended by current American College of Cardiology / American Heart Association guidelines. ^bSee Tables 3 and 5 for recommendations for rosuvastatin and *ABCG2* and Tables 2–6 for recommendation for fluvastatin and *CYP2C9*. ^cDose recommendations are based solely on pharmacokinetic data.




FIGURE 1 SLC01B1 recommendations with intensity and statin dose stratified by SLC01B1 phenotype; all doses assume adult dosing. SAMS, statin-associated musculoskeletal symptoms.

Table 2 Dosing recommendations for statins based on SLC01B1 phenotype in adults

Phenotype	Implications	Dosing recommendations	Classification of recommendations ^a	Considerations
All statins				
SLCO1B1 increased function	Typical myopathy risk and statin exposure	Prescribe desired starting dose and adjust doses based on disease-specific guidelines	Strong	The potential for drug–drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin
SLCO1B1 normal function	Typical myopathy risk and statin exposure	Prescribe desired starting dose and adjust doses based on disease-specific guidelines	Strong	The potential for drug–drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin
Atorvastatin				
SLCO1B1 decreased function or SLC01B1 possible decreased function	Increased atorvastatin exposure as compared with normal function, which may translate to increased myopathy risk	Prescribe ≤40 mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40-mg dose. If dose >40 mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus nonstatin guideline-directed medical therapy) ³	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
SLCO1B1 poor function	Increased atorvastatin exposure as compared with normal and decreased function, which may translate to increased myopathy risk	Prescribe ≤20 mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >20 mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus nonstatin guideline-directed medical therapy) ³	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
Fluvastatin				
SLCO1B1 decreased function or SLC01B1 possible decreased function	Increased fluvastatin exposure as compared with normal function; typical myopathy risk with doses ≤40 mg	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40 mg per day	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
SLCO1B1 poor function	Increased fluvastatin exposure as compared with normal and decreased function; typical myopathy risk with doses ≤40 mg	Prescribe ≤40 mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40 mg per day but higher potency is needed, a higher dose (>40 mg) or an alternative statin (see Figure 1 for recommendations for alternative statins) or combination therapy (i.e., fluvastatin plus nonstatin guideline-directed medical therapy) ³ could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40 mg per day	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy

(Continued)

Table 2 (Continued)

Phenotype	Implications	Dosing recommendations	Classification of recommendations ^a	Considerations
Lovastatin				
SLCO1B1 decreased function or SLCO1B1 possible decreased function	Increased lovastatin acid exposure as compared with normal function, which may translate to increased myopathy risk	Prescribe an alternative statin depending on the desired potency (see Figure 1 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20 mg/day	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
SLCO1B1 poor function	Increased lovastatin acid exposure as compared with normal and decreased function, which may translate to increased myopathy risk	Prescribe an alternative statin depending on the desired potency (see Figure 1 for recommendations for alternative statins)	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
Pitavastatin				
SLCO1B1 decreased function or SLCO1B1 possible decreased function	Increased pitavastatin exposure as compared with normal function, which may translate to increased myopathy risk	Prescribe ≤2 mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1 mg. If dose >2 mg needed for desired efficacy, consider an alternative statin (see Figure 1 for recommendations for alternative statins) or combination therapy (i.e., pitavastatin plus nonstatin guideline-directed medical therapy) ³	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
SLCO1B1 Poor Function	Increased pitavastatin exposure as compared with normal and decreased function, which may translate to increased myopathy risk	Prescribe ≤1 mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose >1 mg needed for desired efficacy, consider an alternative statin (see Figure 1 for recommendations for alternative statins) or combination therapy (i.e., pitavastatin plus nonstatin guideline-directed medical therapy) ³	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
Pravastatin				
SLCO1B1 decreased function or SLCO1B1 possible decreased function	Increased pravastatin exposure as compared with normal function; typical myopathy risk with doses ≤40 mg	Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40 mg per day	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy

(Continued)

Table 2 (Continued)

Phenotype	Implications	Dosing recommendations	Classification of recommendations ^a	Considerations
SLCO1B1 poor function	Increased pravastatin statin exposure as compared with normal and decreased function; typical myopathy risk with doses ≤40 mg	Prescribe ≤40 mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40-mg dose but higher potency is needed, a higher dose (>40 mg) or an alternative statin (see Figure 1 for recommendations for alternative statins) or combination therapy (i.e., pravastatin plus nonstatin guideline-directed medical therapy) ³ could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses >40 mg	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
Rosuvastatin				
SLCO1B1 decreased function or SLCO1B1 possible decreased function	Increased rosuvastatin exposure as compared with normal function; typical myopathy risk with doses ≤20 mg	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20 mg	Strong	The potential for drug–drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
SLCO1B1 poor function	Increased rosuvastatin exposure as compared with normal function and decreased function; typical myopathy risk with doses ≤20 mg	Prescribe ≤20 mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. If dose >20 mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus nonstatin guideline-directed medical therapy) ³	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
Simvastatin				
SLCO1B1 decreased function or SLCO1B1 possible decreased function	Increased simvastatin acid exposure as compared with normal function; increased risk of myopathy	Prescribe an alternative statin depending on the desired potency (see Figure 1 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20 mg/day	Strong	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
SLCO1B1 poor function	Increased simvastatin acid exposure compared with normal and decreased function; highly increased myopathy risk	Prescribe an alternative statin depending on the desired potency (see Figure 1 for recommendations for alternative statins)	Strong	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy

^aRating scheme described in the **Supplemental Material**.

Table 3 Dosing recommendations for rosuvastatin based on ABCG2 phenotype in adults

Phenotype	Implications	Dosing recommendations	Classification of recommendations ^a	Considerations
Normal function	Typical myopathy risk and rosuvastatin exposure	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines	Strong	The potential for drug–drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin
Decreased function	Increased rosuvastatin exposure as compared with normal function; unknown risk for myopathy; increased lipid-lowering effects	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and population-specific guidelines	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
Poor function	Increased rosuvastatin exposure compared with normal and decreased function; unknown myopathy risk; increased lipid-lowering effects	Prescribe ≤20 mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. If dose >20 mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus nonstatin guideline-directed medical therapy) ³	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy

^aRating scheme described in the **Supplemental Material**.

Table 4 Dosing recommendations for fluvastatin based on CYP2C9 phenotype in adults

Phenotype	Implication	Dosing recommendations	Classification of recommendations ^a	Considerations
CYP2C9 normal metabolizer	Normal exposure	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines	Strong	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin
CYP2C9 intermediate metabolizer AS of 1 and 1.5	Increased fluvastatin exposure as compared with normal metabolizer, which may translate to increased myopathy risk	Prescribe ≤40 mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40 mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus nonstatin guideline-directed medical therapy) ³	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy
CYP2C9 poor metabolizer AS 0.5 and 0	Increased fluvastatin exposure as compared with normal and intermediate metabolizer, which may translate to increased myopathy risk	Prescribe ≤20 mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20 mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus nonstatin guideline-directed medical therapy) ³	Moderate	The potential for drug–drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug–drug interactions may be more pronounced, resulting in a higher risk of myopathy

AS, activity score.

^aRating scheme described in the **Supplemental Material**.

Table 5 Combined recommendation for rosuvastatin based on SLC01B1 and ABCG2 phenotype in adults

	ABCG2 normal function	ABCG2 decreased function	ABCG2 poor function
SLC01B1 increased function	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. STRONG	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. MODERATE	Prescribe ≤20 mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. If dose >20 mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus nonstatin guideline-directed medical therapy). ³ OPTIONAL
SLC01B1 normal function	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. STRONG	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. MODERATE	Prescribe ≤20 mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. If dose >20 mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus nonstatin guideline-directed medical therapy). ³ OPTIONAL
SLC01B1 decreased function or possible SLC01B1 decreased function	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20 mg. STRONG	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20 mg. MODERATE	Prescribe ≤10 mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. If dose >10 mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus nonstatin guideline-directed medical therapy). ³ OPTIONAL
SLC01B1 poor function	Prescribe ≤20 mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. If dose >20 mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus nonstatin guideline-directed medical therapy). ³ MODERATE	Prescribe ≤20 mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. If dose >20 mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus nonstatin guideline-directed medical therapy). ³ MODERATE	Prescribe ≤10 mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population-specific guidelines. If dose >10 mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus nonstatin guideline-directed medical therapy). ³ OPTIONAL

Rating scheme described in the **Supplemental Material**. Classification of Recommendations in all caps.

Recommendations for incidental findings

CPIC has published guidelines for utilizing *CYP2C9* genotype for prescribing phenytoin, nonsteroidal anti-inflammatory drugs, and warfarin.^{20–23}

Other considerations

Other factors influencing SAMS. Other factors known to influence a patient's risk for developing SAMS include increased statin dose, drug interactions, advanced age, small body mass index, female gender, metabolic comorbidities (e.g., hypothyroidism), intense physical exercise, and Asian or African ancestry^{25,38–41} (see **Supplement**).

Because polypharmacy is common in the elderly, the association with age is often partly attributed to drug–drug interactions (see below) as well as increases in the frequency of chronic renal or hepatic disease.⁴²

Statin dose is the strongest independent predictor of myopathy risk. The risk of SAMS is approximately sixfold higher in patients on high-dose than lower-dose statin therapy.⁴³ Among all statins, a growing body of evidence suggests that the influence of dose may be greatest for simvastatin.⁴⁴ The exact molecular mechanism of SAMS is unclear, and evidence supports both direct and indirect myotoxic effects of statins on skeletal muscle, possibly mediated through changes in the balance of isoprenoids accompanying the inhibition of skeletal muscle HMG CoA reductase.^{45–47}

Table 6 Combined recommendation for fluvastatin based on SLC01B1 and CYP2C9 phenotype in adults

	CYP2C9 normal metabolizer	CYP2C9 intermediate metabolizer	CYP2C9 poor metabolizer
SLCO1B1 increased function	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. STRONG	Prescribe ≤ 40 mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose > 40 mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus nonstatin guideline-directed medical therapy). ³ MODERATE	Prescribe ≤ 20 mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose > 20 mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus nonstatin guideline-directed medical therapy). ³ MODERATE
SLCO1B1 normal function	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. STRONG	Prescribe ≤ 40 mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose > 40 mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus nonstatin guideline-directed medical therapy). ³ MODERATE	Prescribe ≤ 20 mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose > 20 mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus nonstatin guideline-directed medical therapy). ³ MODERATE
SLCO1B1 decreased function or possible decreased function	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses > 40 mg per day. MODERATE	Prescribe ≤ 20 mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose > 20 mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus nonstatin guideline-directed medical therapy). ³ OPTIONAL	Prescribe an alternative statin depending on the desired potency (see Figure 1 for recommendations for alternative statins). OPTIONAL
SLCO1B1 poor function	Prescribe ≤ 40 mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40 mg per day but higher potency is needed, a higher dose (> 40 mg) or an alternative statin (see Tables 2–6 and Figure 1 for recommendations for alternative statins) or combination therapy (i.e., fluvastatin plus nonstatin guideline-directed medical therapy) ³ could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses > 40 mg per day. MODERATE	Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 for recommendations for alternative statins). OPTIONAL	Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 for recommendations for alternative statins). OPTIONAL

Rating scheme described in the **Supplemental Material**. Classification of Recommendations in all caps.

Drug–drug interactions. In the context of statin monotherapy, myopathy rates are low.⁴⁸ The frequency of this adverse drug reaction increases with coadministration of medications altering the pharmacokinetics of statins (e.g., coadministration with cyclosporine (SLCO1B1 and ABCG2 interaction), gemfibrozil

(SLCO1B1 and CYP2C8 (fluvastatin only) interaction) or calcium channel blockers (CYP3A4/5 interaction)). See the **Supplemental Material** for more information. A list of inhibitors for CYP3A, CYP2C9, SLC01B1, ABCG2, CYP3A4, and CYP2C8 is available on the US Food and Drug Administration (FDA) site.⁴⁹

POTENTIAL BENEFITS AND RISKS FOR THE PATIENT

Based on the highly prevalent use of statins, one potential benefit of preemptive *SLCO1B1*, *ABCG2*, and *CYP2C9* testing may be a reduction in the incidence of SAMS, by identifying those at significant risk and recommending a lower statin dose or an alternative statin with lower SAMS risk. While prospective data showing that prescribing based on genetic testing results alter SAMS incidence are lacking, there are emerging data demonstrating an improvement in patients' perceptions of statins, appropriate statin prescribing, neutral data on patient-reported adherence, and mixed data on reducing LDL-cholesterol levels^{50,51} as other potential benefits of applying *SLCO1B1* testing to clinical practice.

A possible risk could be an error in genotyping. Because genotypes are lifelong test results, any such error could stay in the medical record for the life of the patient. An error in genotyping could result in a decrease in statin dose that was not otherwise necessary and could result in inadequate lipid-lowering therapy. However, this risk can be minimized by (i) monitoring to ensure that the appropriate LDL-cholesterol reduction is achieved for the intended statin intensity and (ii) using an alternative statin with a similar statin intensity based on the recommendation in **Figure 1**. Another potential risk is that a patient or provider may inappropriately stop or avoid statin therapy, and this could cause higher LDL-cholesterol and increased cardiovascular risk.

CAVEATS: APPROPRIATE USE AND/OR POTENTIAL MISUSE OF GENETIC TESTS

As with any diagnostic test, genetic variation is just one factor that clinicians should consider when prescribing statins. Furthermore, rare variants may not be included in the genotype test used, and patients with rare variants that reduce *SLCO1B1* function may be incorrectly assigned a normal phenotype based on a default to wild-type (*1) test result.

In summary, statins are a powerful class of medications for lowering LDL cholesterol and cardiovascular risk with an established track record of safety and efficacy. However, statin-related musculoskeletal symptoms are the most frequently cited reason for discontinuing statin therapy. Although clinicians are well-tuned to trial stopping and later reinitiating statin therapy in those who develop SAMS, in many patients statin therapy is never restarted. As a result, LDL cholesterol values are higher as is their risk for cardiovascular disease. We applied a rigorous approach evaluating the collective evidence around *SLCO1B1*, *ABCG2*, and *CYP2C9* on systemic drug exposure and risk of SAMS. Our evidenced-based recommendations for genotype-guided statin therapy are focused on reducing the risk of SAMS. Based on this foundation, future research can evaluate the extent to which implementation of these guidelines impacts prescribing, SAMS risk, statin adherence, LDL cholesterol levels, and risk for cardiovascular events in patients prescribed statin therapy.

DISCLAIMER

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert consensus based on clinical

evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision making, as well as to identify questions for further research. New evidence may have emerged since the time a guideline was submitted for publication. Guidelines are limited in scope and are not applicable to interventions or diseases not specifically identified. Guidelines do not account for all individual variation among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the healthcare provider to determine the best course of treatment for the patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be solely made by the clinician and the patient. CPIC assumes no responsibility for any injury to persons or damage to property related to any use of CPIC's guidelines, or for any errors or omissions.

SUPPORTING INFORMATION

Supplementary information accompanies this paper on the *Clinical Pharmacology & Therapeutics* website (www.cpt-journal.com).

ACKNOWLEDGMENTS

We acknowledge the critical input of Mary V. Relling (St Jude Children's Research Hospital) and the members of the Clinical Pharmacogenetics Implementation Consortium (CPIC).

FUNDING

This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264 and U24HG010135) and The Pharmacogenomics Knowledgebase (PharmGKB) (U24 HG010615). Additional author support includes P50GM115318 (R.M.K.), HL143161 (S.T.), U01HG007269 (R.M.C.-D.), R01GM117163 (K.M.G., S.W.Y.), and K08HL146990 (J.A.L.). M.N. is funded by a European Research Council ERC Consolidator Grant (Grant agreement 725249).

CONFLICTS OF INTEREST

The authors declared no competing interests for this work. As Deputy Editor-in-Chief of *Clinical Pharmacology & Therapeutics*, Kathleen M. Giacomini was not involved in the review or decision process for this paper.

© 2022 The Authors. *Clinical Pharmacology & Therapeutics* © 2022 American Society for Clinical Pharmacology and Therapeutics

1. Wilke, R.A. *et al.* The clinical pharmacogenomics implementation consortium: CPIC guideline for *SLCO1B1* and simvastatin-induced myopathy. *Clin. Pharmacol. Ther.* **92**, 112–117 (2012).
2. Ramsey, L.B. *et al.* The Clinical Pharmacogenetics Implementation Consortium guideline for *SLCO1B1* and simvastatin-induced myopathy: 2014 update. *Clin. Pharmacol. Ther.* **96**, 423–428 (2014).
3. Grundy, S.M. *et al.* 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J. Am. Coll. Cardiol.* **73**, 3168–3209 (2019).
4. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. *Pharmacol. Rev.* **63**, 157–181 (2011).
5. Turner, R.M. & Pirmohamed, M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. *J. Clin. Med.* **9**, 22 (2019).

6. Clinical Pharmacogenetics Implementation Consortium (CPIC). *CPIC guideline for statins and SLC01B1, ABCG2 and CYP2C9*. <<https://cpicpgx.org/guidelines/cpic-guideline-for-statins/>>. Accessed August 1, 2021. 2021.
7. Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB). *PGx Gene-Specific Information Tables* <<https://www.pharmgkb.org/page/pgxGeneRef>>.
8. PharmVar. *Pharmacogene Variation Consortium* <<https://www.pharmvar.org/>>. Accessed October 18, 2021.
9. Sangkuhl, K. et al. PharmVar GeneFocus: CYP2C9. *Clin. Pharmacol. Ther.* **110**, 662–676 (2021).
10. Lee, C.R., Goldstein, J.A. & Pieper, J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the *in-vitro* and human data. *Pharmacogenetics* **12**, 251–263 (2002).
11. Gaedigk, A. et al. The evolution of PharmVar. *Clin. Pharmacol. Ther.* **105**, 29–32 (2019).
12. Scott, S.A. et al. Development and analytical validation of a 29 gene clinical pharmacogenetic genotyping panel: multi-ethnic allele and copy number variant detection. *Clin. Transl. Sci.* **14**, 204–213 (2021).
13. Ramsey, L.B. et al. Rare versus common variants in pharmacogenetics: *SLCO1B1* variation and methotrexate disposition. *Genome Res.* **22**, 1–8 (2012).
14. Ramsey, L.B. et al. Genome-wide study of methotrexate clearance replicates *SLCO1B1*. *Blood* **121**, 898–904 (2013).
15. van de Steeg, E. et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. *J. Clin. Invest.* **122**, 519–528 (2012).
16. Heyes, N., Kapoor, P. & Kerr, I.D. Polymorphisms of the multidrug pump ABCG2: a systematic review of their effect on protein expression, function, and drug pharmacokinetics. *Drug Metab. Dispos.* **46**, 1886–1899 (2018).
17. Eckenstaler, R. & Benndorf, R.A. The role of ABCG2 in the pathogenesis of primary hyperuricemia and gout—an update. *Int. J. Mol. Sci.* **22**, 6678 (2021).
18. Brackman, D.J. et al. Genome-wide association and functional studies reveal novel pharmacological mechanisms for allopurinol. *Clin. Pharmacol. Ther.* **106**, 623–631 (2019).
19. Saison, C. et al. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior. *Nat. Genet.* **44**, 174–177 (2012).
20. Caudle, K.E. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. *Clin. Pharmacol. Ther.* **96**, 542–548 (2014).
21. Johnson, J.A. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. *Clin. Pharmacol. Ther.* **102**, 397–404 (2017).
22. Karnes, J.H. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update. *Clin. Pharmacol. Ther.* **109**, 302–309 (2021).
23. Theken, K.N. et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. *Clin. Pharmacol. Ther.* **108**, 191–200 (2020).
24. Gu, Q., Paulose-Ram, R., Burt, V.L. & Kit, B.K. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012. In: *NCHS data brief, no 177*. (National Center for Health Statistics, Hyattsville, 2014).
25. Wilke, R.A. et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. *Nat. Rev. Drug. Discov.* **6**, 904–916 (2007).
26. Alfirevic, A. et al. Phenotype standardization for statin-induced myotoxicity. *Clin. Pharmacol. Ther.* **96**, 470–476 (2014).
27. Abd, T.T. & Jacobson, T.A. Statin-induced myopathy: a review and update. *Expert Opin. Drug Saf.* **10**, 373–387 (2011).
28. Buettner, C., Ripberger, M.J., Smith, J.K., Leveille, S.G., Davis, R.B. & Mittleman, M.A. Statin use and musculoskeletal pain among adults with and without arthritis. *Am. J. Med.* **125**, 176–182 (2012).
29. Serban, M.C. et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. *J. Am. Coll. Cardiol.* **69**, 1386–1395 (2017).
30. Cohen, J.D., Brinton, E.A., Ito, M.K. & Jacobson, T.A. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. *J. Clin. Lipidol.* **6**, 208–215 (2012).
31. Keskitalo, J.E., Zolk, O., Fomm, M.F., Kurkinen, K.J., Neuvonen, P.J. & Niemi, M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. *Clin. Pharmacol. Ther.* **86**, 197–203 (2009).
32. Chasman, D.I., Giulianini, F., MacFadyen, J., Barratt, B.J., Nyberg, F. & Ridker, P.M. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. *Circ. Cardiovasc. Genet.* **5**, 257–264 (2012).
33. Wilke, R.A., Reif, D.M. & Moore, J.H. Combinatorial pharmacogenetics. *Nat. Rev. Drug Discov.* **4**, 911–918 (2005).
34. SEARCH Collaborative Group et al. *SLCO1B1* variants and statin-induced myopathy—a genomewide study. *N. Engl. J. Med.* **359**, 789–799 (2008).
35. Wagner, J.B. et al. Impact of *SLCO1B1* genetic variation on rosuvastatin systemic exposure in pediatric hypercholesterolemia. *Clin. Transl. Sci.* **13**, 628–637 (2020).
36. Wagner, J.B. et al. Impact of genetic variation on pravastatin systemic exposure in pediatric hypercholesterolemia. *Clin. Pharmacol. Ther.* **105**, 1501–1512 (2019).
37. Wagner, J.B. et al. Impact of *SLCO1B1* genotype on pediatric simvastatin acid pharmacokinetics. *J. Clin. Pharmacol.* **58**, 823–833 (2018).
38. de Lemos, J.A. et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA* **292**, 1307–1316 (2004).
39. Chung, J.Y. et al. Effect of OATP1B1 (*SLCO1B1*) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. *Clin. Pharmacol. Ther.* **78**, 342–350 (2005).
40. Lee, E. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. *Clin. Pharmacol. Ther.* **78**, 330–341 (2005).
41. Hippisley-Cox, J. & Coupland, C. Individualising the risks of statins in men and women in England and Wales: population-based cohort study. *Heart* **96**, 939–947 (2010).
42. Thompson, P.D., Clarkson, P. & Karas, R.H. Statin-associated myopathy. *JAMA* **289**, 1681–1690 (2003).
43. McClure, D.L., Valuck, R.J., Glanz, M., Murphy, J.R. & Hokanson, J.E. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. *J. Clin. Epidemiol.* **60**, 812–818 (2007).
44. Link, E. et al. *SLCO1B1* variants and statin-induced myopathy—a genomewide study. *N. Engl. J. Med.* **359**, 789–799 (2008).
45. Ananthakumar, A., Liu, Y., Fernandez, C.E., Truskey, G.A. & Voora, D. Modeling statin myopathy in a human skeletal muscle microphysiological system. *PLoS One* **15**, e0242422 (2020).
46. Osaki, Y. et al. Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: a model for statin-induced myopathy. *Biochem. Biophys. Res. Commun.* **466**, 536–540 (2015).
47. Schirris, T.J.J. et al. Statin-induced myopathy is associated with mitochondrial complex III inhibition. *Cell Metab.* **22**, 399–407 (2015).
48. Graham, D.J. et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. *JAMA* **292**, 2585–2590 (2004).
49. US Food and Drug Administration. Drug development and drug interactions | table of substrates, inhibitors and inducers <<https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers>>. Accessed Aug. 30, 2021.
50. Vassy, J.L. et al. Effect of pharmacogenetic testing for statin myopathy risk vs usual care on blood cholesterol: a randomized clinical trial. *JAMA Netw. Open* **3**, e2027092 (2020).
51. Peyser, B. et al. Effects of delivering *SLCO1B1* pharmacogenetic information in randomized trial and observational settings. *Circ. Genom. Precis. Med.* **11**, e002228 (2018).